

**UPDATED INTERNATIONAL CLINICAL PRACTICE GUIDELINES INCLUDING GUIDANCE  
FOR DIRECT ORAL ANTICOAGULANTS IN THE TREATMENT AND PROPHYLAXIS  
OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER**

*Revised guidelines provide first-time guidance for the appropriate use of the direct oral anticoagulants in cancer patients based on the current level of evidence*

**SAN DIEGO, US, DECEMBER 2, 2016** -- The International Initiative on Thrombosis and Cancer (ITAC-CME) announced on October 5, the publication of its updated 2016 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer in *The Lancet Oncology*.

[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(16\)30369-2/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30369-2/abstract)

Endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the **2016 ITAC-CME International clinical practice guidelines** include recommendations for treatment and prophylaxis for both in-hospital and outpatient cancer-associated VTE in specific cancer patient subgroups, based on a systematic review of the literature up to January 2016. Guidance is provided for the appropriate use of the direct oral anticoagulants in the treatment of VTE in cancer patients.

“ITAC-CME was established to reduce the global burden of VTE in cancer,” said lead author Pr. Dominique Farge, Professor of Internal Medicine and Vascular Disease, St Louis Hospital, Paris Diderot University, France. “This update to our 2013 international guidelines provides clinicians with important information about advances in treatment options, including guidance on the use of direct oral anticoagulants.”

To help clinicians put the guidelines into practice, ITAC-CME has developed accredited online continuing professional development (CPD) programs and updated its free mobile app “International VTE & Cancer Guidelines.” The CPD programs and the app (available from the iOS App Store, Google Play and online at <https://www.itaccme.com/en/practice-guidelines/guidelines-app>) will be launched in January 2017.

**About ITAC-CME**

ITAC-CME (<https://www.itaccme.com>) is a multidisciplinary group of clinicians and researchers from across the globe. Through education of physicians, nurses, and allied health professionals globally, ITAC-CME is committed to disseminating relevant and peer-reviewed prophylaxis and treatment guidelines for VTE in cancer that will help to reduce a substantial economic burden on health care systems and improve the lives of millions of patients worldwide.

**Corresponding Author:**

Professor Dominique Farge-Bancel

Unité Clinique de Médecine Interne, Maladies  
Autoimmunes et Pathologie Vasculaire, UF 04,

Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, INSERM UMRS 1160, Paris Denis  
Diderot Université, France

[dominique.farge-bancel@aphp.fr](mailto:dominique.farge-bancel@aphp.fr)

